fenofibrate has been researched along with Atherosclerosis in 59 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-eight patients with impaired fasting glucose (IFG), fifty-six subjects with impaired glucose tolerance (IGT) and fifty-five normolipidemic control subjects with asymptomatic atherosclerosis, were treated for 90 days with either micronized fenofibrate (200 mg/day) or placebo." | 7.76 | The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. ( Krysiak, R; Okopien, B, 2010) |
| "Fenofibrate reduces atherosclerosis more than can be explained by lowering total plasma cholesterol per se." | 7.73 | Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. ( de Vries-van der Weij, J; Kleemann, R; Koenig, W; Kooistra, T; Princen, HM; Toet, K; Verschuren, L, 2006) |
| "In patients with type 2 diabetes, fenofibrate is effective in reducing the progression of coronary artery disease, as demonstrated by the Diabetes Atherosclerosis Intervention Study (DAIS)." | 6.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| "Patients (n = 300) with type II diabetes, mixed dyslipidemia (2 or more of low-density lipoprotein > or =100 mg/dl, triglycerides > or =200 mg/dl, or high-density lipoprotein <40 mg/dl), and no history of coronary heart disease were randomly assigned to receive simvastatin 20 mg, fenofibrate 160 mg, or a combination of simvastatin 20 mg and fenofibrate 160 mg daily." | 5.12 | The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. ( Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD, 2006) |
| "In an experimental rabbit model, it appears that colchicine statistically significantly reduces the development of atherosclerosis of the aorta, especially in combination with NAC." | 4.02 | The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. ( Doulamis, IP; Iliopoulos, DC; Kaminiotis, VV; Kapelouzou, A; Kontogiannis, C; Mastrogeorgiou, M; Mylonas, KS; Nikiteas, N; Siasos, G; Spartalis, E; Spartalis, M; Toutouzas, K, 2021) |
| "These results demonstrate that: (a) F(1)B hamster is more sensitive to developing diet-induced hyperlipidemia and atherosclerosis; and (b) the greater antiatherosclerotic efficacy of fenofibrate occurred primarily via reductions in proatherogenic lipoproteins." | 3.77 | Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters. ( Srivastava, RA, 2011) |
| "Fenofibrate, a drug in the fibrate class of amphiphathic carboxylic acids, has multiple blood lipid modifying actions, which are beneficial to the prevention of atherosclerosis." | 3.77 | Fenofibrate, a peroxisome proliferator-activated receptor α agonist, alters triglyceride metabolism in enterocytes of mice. ( Buhman, KK; Cheng, JX; Slipchenko, MN; Uchida, A, 2011) |
| "Fifty-eight patients with impaired fasting glucose (IFG), fifty-six subjects with impaired glucose tolerance (IGT) and fifty-five normolipidemic control subjects with asymptomatic atherosclerosis, were treated for 90 days with either micronized fenofibrate (200 mg/day) or placebo." | 3.76 | The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. ( Krysiak, R; Okopien, B, 2010) |
| " In this study, we aimed to: a) evaluate hamster as a model for insulin resistance, hyperlipidemia and atherosclerosis; and b) investigate the effect of a PPAR-α activator, fenofibrate, in this model." | 3.76 | Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. ( He, S; Srivastava, RA, 2010) |
| "Fenofibrate has shown to reduce major cardiovascular events and slow angiographic progression of coronary atherosclerosis." | 3.74 | Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. ( Badimon, JJ; Corti, R; Fallon, JT; Fuster, V; Hutter, R; Mizsei, G; Osende, J; Valdivieso, C; Viles-Gonzalez, JF; Zafar, U, 2007) |
| " We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM)." | 3.74 | Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. ( Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R, 2007) |
| "NO deficiency and activation of inflammation are involved in vascular impairment in rats with high-fat diet-induced hyperlipidemia, and fenofibrate can effectively prevent atherosclerosis by restoring NO concentration and down-regulating VCAM-1 expression in these rats." | 3.74 | [Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats]. ( Guo, HS; He, ZC; Lin, JC; Ou, BR; Sun, M; Wu, J, 2007) |
| "Fenofibrate reduces atherosclerosis more than can be explained by lowering total plasma cholesterol per se." | 3.73 | Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. ( de Vries-van der Weij, J; Kleemann, R; Koenig, W; Kooistra, T; Princen, HM; Toet, K; Verschuren, L, 2006) |
| "Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)." | 2.61 | New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019) |
| " However, this combination is often associated with adverse eff ects, especially muscular and hepatic." | 2.50 | [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies]. ( Hernández Mijares, A, 2014) |
| "In patients with type 2 diabetes, fenofibrate is effective in reducing the progression of coronary artery disease, as demonstrated by the Diabetes Atherosclerosis Intervention Study (DAIS)." | 2.44 | Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. ( Steiner, G, 2008) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "Fenofibrate was not associated with improved carotid IMT in adults with type 2 diabetes when compared with placebo, despite a statistically significant improvement in TC, LDL-C and TG at 2 and 4 years, and HDL-C at 4 months and 2 years." | 1.48 | Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Skilton, MR; Veillard, AS; Watts, GF, 2018) |
| "AF-LIP may be beneficial for the treatment of atherosclerosis, since atherosclerosis is one of the secondary complications of hyperlipidemia." | 1.40 | Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models. ( Ashok, P; Poulose, DN; Singh, D; Suresh, B, 2014) |
| " Interactions between statins and other drugs are caused by pharmacokinetic mechanisms, mainly by changing the metabolism of statins in the CYP450 enzyme system, in the hepatic glucuronidation pathway or in the transporters responsible for statin distribution in tissues." | 1.40 | [The combinations of statins and fibrates: pharmacokinetic and clinical implications]. ( González Santos, P, 2014) |
| "Fenofibrate treatment resulted in significant reductions in TG concentrations by 24." | 1.37 | Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. ( Arnett, D; Cao, J; Dong, Y; Hanson, NQ; Kabagambe, E; Ordovas, J; Steffen, BT; Straka, R; Tsai, AK; Tsai, MY; Zhou, X, 2011) |
| "Rosiglitazone treatment had no effect on protein levels but reduced activity by 73% of the control (P<0." | 1.35 | Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment. ( Clancy, P; Golledge, J; Mangan, S, 2008) |
| "Fenofibrate treatment significantly improved lipoprotein metabolism toward a less atherogenic phenotype but did not affect insulin sensitivity." | 1.33 | PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. ( Fiévet, C; Fruchart, JC; Hennuyer, N; Mezdour, H; Staels, B; Tailleux, A; Torpier, G, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (42.37) | 29.6817 |
| 2010's | 30 (50.85) | 24.3611 |
| 2020's | 4 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Spartalis, M | 2 |
| Siasos, G | 2 |
| Mastrogeorgiou, M | 1 |
| Spartalis, E | 2 |
| Kaminiotis, VV | 1 |
| Mylonas, KS | 1 |
| Kapelouzou, A | 1 |
| Kontogiannis, C | 1 |
| Doulamis, IP | 1 |
| Toutouzas, K | 1 |
| Nikiteas, N | 1 |
| Iliopoulos, DC | 2 |
| Tzima, I | 1 |
| Anastasiou, A | 1 |
| Krysiak, R | 5 |
| Kowalcze, K | 1 |
| Okopień, B | 5 |
| Fruchart, JC | 5 |
| Santos, RD | 1 |
| Yamashita, S | 1 |
| Masuda, D | 1 |
| Matsuzawa, Y | 1 |
| Harmer, JA | 1 |
| Keech, AC | 1 |
| Veillard, AS | 1 |
| Skilton, MR | 1 |
| Watts, GF | 2 |
| Celermajer, DS | 1 |
| Garg, G | 1 |
| Patil, A | 1 |
| Singh, J | 1 |
| Kaushik, N | 1 |
| Praksah, A | 1 |
| Pal, A | 1 |
| Chakrabarti, A | 1 |
| Preston Mason, R | 1 |
| Kei, A | 1 |
| Liberopoulos, E | 2 |
| Tellis, K | 1 |
| Rizzo, M | 1 |
| Elisaf, M | 3 |
| Tselepis, A | 1 |
| Sahebkar, A | 1 |
| Chew, GT | 1 |
| Ashok, P | 1 |
| Singh, D | 1 |
| Poulose, DN | 1 |
| Suresh, B | 1 |
| González Santos, P | 1 |
| Díaz Rodríguez, Á | 1 |
| Mantilla, T | 1 |
| Hernández Mijares, A | 1 |
| González, DF | 1 |
| Gdula-Dymek, A | 3 |
| Marek, B | 2 |
| Aguiar, C | 1 |
| Alegria, E | 1 |
| Bonadonna, RC | 1 |
| Catapano, AL | 1 |
| Cosentino, F | 1 |
| Farnier, M | 1 |
| Ferrières, J | 1 |
| Filardi, PP | 1 |
| Hancu, N | 1 |
| Kayikcioglu, M | 1 |
| Mello E Silva, A | 1 |
| Millan, J | 1 |
| Reiner, Ž | 1 |
| Tokgozoglu, L | 1 |
| Valensi, P | 1 |
| Viigimaa, M | 1 |
| Vrablik, M | 1 |
| Zambon, A | 1 |
| Zamorano, JL | 1 |
| Ferrari, R | 1 |
| Rosolová, H | 1 |
| Márk, L | 1 |
| Dani, G | 1 |
| van der Krieken, SE | 1 |
| Popeijus, HE | 1 |
| Konings, M | 1 |
| Dullens, SP | 1 |
| Mensink, RP | 1 |
| Plat, J | 1 |
| Handelsman, Y | 1 |
| Shapiro, MD | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Mansouri, RM | 2 |
| Baugé, E | 3 |
| Gervois, P | 2 |
| Fruchart-Najib, J | 1 |
| Fiévet, C | 2 |
| Staels, B | 7 |
| Shi, HY | 1 |
| Ge, JB | 1 |
| Fang, WY | 1 |
| Yao, K | 1 |
| Sun, AJ | 1 |
| Huang, RC | 1 |
| Jia, QZ | 1 |
| Wang, KQ | 1 |
| Zou, YZ | 1 |
| Cao, XT | 1 |
| Steiner, G | 1 |
| Tsimihodimos, V | 1 |
| Laakso, M | 1 |
| Pérez, A | 1 |
| Srivastava, RA | 2 |
| He, S | 1 |
| Dong, Y | 1 |
| Steffen, BT | 1 |
| Cao, J | 1 |
| Tsai, AK | 1 |
| Ordovas, J | 1 |
| Straka, R | 1 |
| Zhou, X | 1 |
| Kabagambe, E | 1 |
| Hanson, NQ | 1 |
| Arnett, D | 1 |
| Tsai, MY | 1 |
| Uchida, A | 1 |
| Slipchenko, MN | 1 |
| Cheng, JX | 1 |
| Buhman, KK | 1 |
| Lalloyer, F | 2 |
| Wouters, K | 1 |
| Baron, M | 2 |
| Caron, S | 1 |
| Vallez, E | 2 |
| Vanhoutte, J | 1 |
| Shiri-Sverdlov, R | 1 |
| Hofker, M | 1 |
| Tailleux, A | 3 |
| Leroyer, AS | 1 |
| Majd, Z | 1 |
| Bantubungi, K | 1 |
| Chinetti-Gbaguidi, G | 2 |
| Delerive, P | 1 |
| Boulanger, CM | 1 |
| Kleemann, R | 2 |
| Bureeva, S | 1 |
| Perlina, A | 1 |
| Kaput, J | 1 |
| Verschuren, L | 2 |
| Wielinga, PY | 1 |
| Hurt-Camejo, E | 1 |
| Nikolsky, Y | 1 |
| van Ommen, B | 1 |
| Kooistra, T | 2 |
| Hennuyer, N | 1 |
| Torpier, G | 1 |
| Mezdour, H | 1 |
| Wu, KK | 1 |
| Wu, TJ | 2 |
| Chin, J | 1 |
| Mitnaul, LJ | 1 |
| Hernandez, M | 1 |
| Cai, TQ | 1 |
| Ren, N | 1 |
| Waters, MG | 1 |
| Wright, SD | 1 |
| Cheng, K | 1 |
| Duriez, P | 1 |
| Robillard, R | 1 |
| Fontaine, C | 1 |
| Chinetti, G | 1 |
| Hersberger, M | 1 |
| von Eckardstein, A | 1 |
| Corti, R | 1 |
| Osende, J | 1 |
| Hutter, R | 1 |
| Viles-Gonzalez, JF | 1 |
| Zafar, U | 1 |
| Valdivieso, C | 1 |
| Mizsei, G | 1 |
| Fallon, JT | 1 |
| Fuster, V | 1 |
| Badimon, JJ | 1 |
| Davidson, MH | 1 |
| Bays, HE | 1 |
| Stein, E | 1 |
| Maki, KC | 1 |
| Shalwitz, RA | 1 |
| Doyle, R | 1 |
| Muhlestein, JB | 1 |
| May, HT | 1 |
| Jensen, JR | 1 |
| Horne, BD | 1 |
| Lanman, RB | 1 |
| Lavasani, F | 1 |
| Wolfert, RL | 1 |
| Pearson, RR | 1 |
| Yannicelli, HD | 1 |
| Anderson, JL | 1 |
| de Vries-van der Weij, J | 1 |
| Koenig, W | 1 |
| Toet, K | 1 |
| Princen, HM | 1 |
| Otsuki, M | 1 |
| Goya, K | 1 |
| Kasayama, S | 1 |
| Ou, HY | 1 |
| Chou, CW | 1 |
| Hsiao, SH | 1 |
| Lin, CY | 1 |
| Kao, PC | 1 |
| Mangan, S | 1 |
| Clancy, P | 1 |
| Golledge, J | 1 |
| Yagil, C | 1 |
| Yagil, Y | 1 |
| Tordjman, KM | 1 |
| Semenkovich, CF | 1 |
| Coleman, T | 1 |
| Yudovich, R | 1 |
| Bak, S | 1 |
| Osher, E | 1 |
| Vechoropoulos, M | 1 |
| Stern, N | 1 |
| Plutzky, J | 1 |
| Bouhlel, MA | 1 |
| Wu, J | 1 |
| Sun, M | 1 |
| Lin, JC | 1 |
| He, ZC | 1 |
| Ou, BR | 1 |
| Guo, HS | 1 |
| Brinton, EA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia[NCT01010516] | Phase 4 | 120 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease[NCT00309712] | 300 participants | Interventional | 2002-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for fenofibrate and Atherosclerosis
| Article | Year |
|---|---|
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib | 2019 |
Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug | 2020 |
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa | 2019 |
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofib | 2014 |
[Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Fenofibrate; Humans; Hydroxymethylgluta | 2014 |
[What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agents | 2015 |
[Diabetic dyslipidaemia and the atherosclerosis].
Topics: Apolipoprotein A-V; Apolipoproteins A; Apolipoproteins C; Atherosclerosis; Cardiovascular Diseases; | 2016 |
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Topics: Atherosclerosis; Cardiovascular Diseases; Fatty Acids, Omega-3; Fenofibrate; Fibric Acids; Humans; H | 2017 |
Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Fenofibrat | 2008 |
Pleiotropic effects of fenofibrate.
Topics: Animals; Atherosclerosis; Disease Progression; Fenofibrate; Gene Expression Regulation; Humans; Hypo | 2009 |
Lipid disorders in type 2 diabetes.
Topics: Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Hu | 2009 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
Fibrates.
Topics: Animals; Atherosclerosis; Bezafibrate; Cholesterol; Clofibrate; Endothelium, Vascular; Fenofibrate; | 2005 |
Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bio | 2005 |
Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Topics: Antihypertensive Agents; Atherosclerosis; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; | 2005 |
Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Fenofibrate; Gemfib | 2008 |
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; D | 2008 |
5 trials available for fenofibrate and Atherosclerosis
| Article | Year |
|---|---|
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-R | 2013 |
The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
Topics: Adult; Aged; Atherosclerosis; Blood Glucose; C-Reactive Protein; Cytokines; Drug Therapy, Combinatio | 2013 |
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
Topics: Adult; Aged; Atherosclerosis; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibr | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Di | 2006 |
Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Topics: Atherosclerosis; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cholesterol; Diabetes Mellitus | 2007 |
37 other studies available for fenofibrate and Atherosclerosis
| Article | Year |
|---|---|
The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits.
Topics: Acetylcysteine; Administration, Oral; Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; C-R | 2021 |
Anti-inflammatory Drug Combination Therapy for Atherosclerosis:\
Colchicine and Fenofibrate
Topics: Anti-Inflammatory Agents; Atherosclerosis; Colchicine; Coronary Artery Disease; Drug Combinations; F | 2022 |
Macroprolactinaemia modulates cardiometabolic effects of fenofibrate in men with atherogenic dyslipidaemia: A pilot study.
Topics: Adult; Atherosclerosis; Case-Control Studies; Dyslipidemias; Fenofibrate; Humans; Hypolipidemic Agen | 2020 |
Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.
Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; | 2018 |
Pharmacological evaluation of Convolvulus pluricaulis as hypolipidaemic agent in Triton WR-1339-induced hyperlipidaemia in rats.
Topics: Animals; Atherosclerosis; Biomarkers; Convolvulus; Disease Models, Animal; Female; Fenofibrate; Hype | 2018 |
Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Dose-Response Relationship, | 2014 |
[The combinations of statins and fibrates: pharmacokinetic and clinical implications].
Topics: Atherosclerosis; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibric Ac | 2014 |
[The fixed combination of pravastatin and fenofibrate: what can it provide?].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hyd | 2014 |
[Achievement of therapeutic objectives].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Dyslipide | 2014 |
[Treatment of older patients with dyslipidemia].
Topics: Age Factors; Aged; Atherosclerosis; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Re | 2014 |
Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Topics: Atherosclerosis; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fe | 2015 |
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysl | 2015 |
The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Fema | 2016 |
[Part IV. Non-lipid effects of fenofibrate therapy].
Topics: Atherosclerosis; Cardiovascular Diseases; Fenofibrate; Humans; Hypolipidemic Agents | 2016 |
C/EBP-β Is Differentially Affected by PPARα Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A-I Production During ER-Stress and Inflammation.
Topics: Apolipoprotein A-I; Atherosclerosis; Butyrates; Caco-2 Cells; CCAAT-Enhancer-Binding Protein-beta; E | 2017 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.
Topics: Animal Feed; Animals; Apolipoprotein A-V; Apolipoprotein E2; Apolipoproteins A; Atherosclerosis; Cho | 2008 |
Peroxisome proliferator-activated receptor alpha agonist attenuates oxidized-low density lipoprotein induced immune maturation of human monocyte-derived dendritic cells.
Topics: Atherosclerosis; Cytokines; Dendritic Cells; Endocytosis; Fenofibrate; Humans; Immunophenotyping; Li | 2008 |
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; D | 2010 |
The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report.
Topics: Adult; Aged; Atherosclerosis; Cytokines; Female; Fenofibrate; Glucose; Glucose Intolerance; Glucose | 2010 |
Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
Topics: Animals; Aorta; Atherosclerosis; Cholesterol; Cricetinae; Dietary Fats; Fenofibrate; Hyperlipidemias | 2010 |
Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cricetinae; Fatty Acids; Female; Fe | 2011 |
Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.
Topics: Atherosclerosis; Biomarkers; Cohort Studies; Dinoprost; Fenofibrate; Genetic Predisposition to Disea | 2011 |
Fenofibrate, a peroxisome proliferator-activated receptor α agonist, alters triglyceride metabolism in enterocytes of mice.
Topics: Animals; Atherosclerosis; Dietary Fats; Enterocytes; Fenofibrate; Humans; Hypolipidemic Agents; Inte | 2011 |
Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Aorta; Apolipoprotein E2; Atherosclerosis; | 2011 |
PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH.
Topics: Animals; Atherosclerosis; Biomarkers; Cell-Derived Microparticles; Disease Models, Animal; Fatty Liv | 2011 |
A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Agents; Drug Design; Fenofibrate; | 2011 |
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; Atherosclerosis; Blood Glucose; Disease Models, Anima | 2005 |
Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiop | 2005 |
Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI.
Topics: Animals; Atherosclerosis; Fenofibrate; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Mag | 2007 |
Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
Topics: Animals; Aorta; Aortic Valve; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Cholesterol; Fe | 2006 |
Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.
Topics: Aorta; Atherosclerosis; Blotting, Western; Carotid Stenosis; Cells, Cultured; Dose-Response Relation | 2008 |
Peroxisome proliferator-activated receptor alpha: friend or foe?
Topics: Animals; Atherosclerosis; Blood Pressure; Docosahexaenoic Acids; Fenofibrate; Humans; Hypertension; | 2007 |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogen | 2007 |
Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Liver; Fen | 2007 |
[Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats].
Topics: Animals; Atherosclerosis; Cell Adhesion; Endothelium, Vascular; Fenofibrate; Hyperlipidemias; Inflam | 2007 |
Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response.
Topics: Acute-Phase Proteins; Animals; Atherosclerosis; Cell Nucleus; Fenofibrate; Gene Expression Regulatio | 2008 |